Medical Policy Revision: Homocysteine Testing in the Screening, Diagnosis and Management of Cardiovascular Diseases
Effective June 22, 2016, Horizon Blue Cross Blue Shield of New Jersey will change the way we consider certain claims for the use of homocysteine testing in the diagnosis and treatment of cardiovascular diseases.
The guidelines of our medical policy, Homocysteine Testing in the Screening, Diagnosis and Management of Cardiovascular Diseases, identify circumstances when the measurement of plasma levels of homocysteine is considered investigational or not medically necessary in the screening, evaluation and management of members who have cardiovascular disease.
We encourage you to review this revised policy in our online Medical Policy Manual.
Based on the guidelines included in our medical policy, Homocysteine Testing in the Screening, Diagnosis and Management of Cardiovascular Diseases AND the submitted diagnosis or diagnoses code(s):
- CPT® code 83090 submitted on claims for services provided on and after June 22, 2016 may be denied as an investigational or not medically necessary service.
Unless Horizon BCBSNJ gives written notice that all or part of the above changes have been cancelled or postponed, the changes will be applied to claims for dates of service on and after June 22, 2016.
CPT® is a registered mark of the American Medical Association.